CJC-1295
5mg
CJC-1295 (no DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of 29 amino acids. Research has studied its ability to increase plasma growth hormone and IGF-1 levels through sustained pulsatile release. The D-Ala modification at position 2 gives it a longer half-life than native GHRH. Often paired with Ipamorelin in GH secretagogue research. Supplied as lyophilised powder, third-party tested, lab certificate published on this page.
Published research on CJC-1295 is indexed on PubMed. See our full UK buyer's guide for CJC-1295.
Intended Use: Strictly for in-vitro laboratory research. Not for use in humans or animals. Not to be used in foods, drugs, or medical diagnostics. This product has not been evaluated by the MHRA or FDA. Buyer assumes full responsibility for safe handling and regulatory compliance.
98%+
Purity
LAB
Certified
SAME
Day Ship
Quantity
Add £19.01 more for free UK delivery
Damaged or lost? Free reshipment guaranteed
CJC-1295 + Ipamorelin 5+5mg
Pre-blended GHRH + GHRP research peptide vial. CJC-1295 (no DAC) and Ipamorelin combined.
All components in a single lyophilised vial. One reconstitution, one inventory line, one CoA.
Research Use Only
This product is intended strictly for research and laboratory use only. Not for human consumption, medical use, or diagnostic purposes.
Certificate of Analysis
Third-party tested
Lyophilised Stability
24 months
Sealed at -20°C, light-protected
Reconstituted Stability
Up to 3 months
Stored at 2-8°C after mixing
Cold-Chain Shipping
Always
Dry-cold pack, Royal Mail Tracked 24
Important Notice
All compounds are sold individually and do not include research supplies. Products are provided in lyophilised (powder) form and require proper reconstitution before use in research settings.
Related Products
Product Specifications
Research Overview
CJC-1295 (no DAC) is a synthetic analogue of growth hormone releasing hormone (GHRH), also referred to as modified GRF 1-29. It binds to GHRH receptors in the anterior pituitary gland to stimulate the synthesis and secretion of growth hormone. The no DAC (Drug Affinity Complex) version lacks the maleimidopropionic acid linker present in CJC-1295 with DAC, resulting in a shorter half-life that produces more pulsatile GH release patterns. Researchers consider this pulsatile pattern more physiologically similar to natural endogenous GH secretion, making CJC-1295 no DAC particularly valuable for studies requiring physiological GH release kinetics. The compound is frequently studied in combination with Ipamorelin, a selective GHS-R1a agonist, for synergistic effects through complementary receptor pathways, CJC-1295 stimulating GH release via the GHRH receptor while Ipamorelin acts at the ghrelin receptor. This dual-pathway approach produces amplified GH pulses and has become a standard research protocol in growth hormone biology. Studies have examined CJC-1295's effects on plasma GH levels, IGF-1 production, body composition, and sleep-related GH secretion patterns.
Product Specifications
Laboratory Handling
- Store lyophilised vials at -20°C for long-term storage. Reconstituted CJC-1295 should be refrigerated at 2-8°C and used within 4 weeks.
- Reconstitute with bacteriostatic water using slow, gentle injection down the vial wall. Swirl to dissolve, do not shake.
- Maintain strict aseptic technique. Sterilise vial stoppers with 70% isopropyl alcohol before each needle insertion.
- Prepare single-use aliquots from reconstituted stock. Repeated freeze-thaw cycling degrades GHRH analogue peptides.
Frequently Asked Questions
CJC-1295
5mg · £25.99